10x Genomics (NASDAQ: TXG) is a leading life sciences technology company that develops and sells innovative instruments and software for single-cell analysis. This cutting-edge biotechnology allows scientists to study individual cells, which is crucial for understanding complex diseases like cancer. 10x Genomics faces competition from firms such as Qiagen, which recently acquired one of its legal rivals, Parse Biosciences.
On September 1, 2026, analyst Dan Leonard of RBC Capital initiated coverage on 10x Genomics. The firm assigned a "Sector Perform" rating and set a price target of $70.00. At the time, the biotechnology stock's price was $62.45, which means the target represents a potential upside of about 12.09% for investors, highlighting a positive investment outlook.
This analyst rating follows a significant legal victory for 10x Genomics. As highlighted by Zacks Investment Research, a jury found that competitor Parse Biosciences willfully infringed on three of 10x Genomics' patents. The verdict awarded 10x Genomics over $4.8 million in damages and confirmed the validity of its intellectual property, strengthening its market position in the competitive life sciences sector.
Future growth prospects are also a key factor for 10x Genomics. A report from Seeking Alpha notes that 10x Genomics' new Atera product is expected to boost instrument sales in late 2026. This innovative product is also projected to create a steady stream of high-margin recurring revenue from consumables starting in 2027, signaling strong biotech innovation.
Currently, 10x Genomics' stock trades at $62.45, with a daily high of $62.62 and a low of $58.70. The company has a market capitalization, or total market value, of approximately $7.93 billion. Over the past 52 weeks, the stock performance has seen it trade between a low of $11.16 and a high of $66.94, providing key investment data for potential shareholders.
